625-56-9Relevant academic research and scientific papers
Methyl acetate reaction with OH and Cl: Reaction rates and products for a biodiesel analogue
Andersen, Vibeke F.,Nilsson, Elna J.K.,J?rgensen, Solvejg,Nielsen, Ole John,Johnson, Matthew S.
, p. 23 - 29 (2009)
Relative rate experiments performed in a photochemical reactor at 293 ± 0.5 K and a total air pressure of 980 mbar were used to determine k(CH3C(O)OCH3 + Cl) = (1.93 ± 0.27) × 10-12 cm3 molecule-1 ss
PYRAZOLE DERIVATIVE
-
Paragraph 0100; 0106; 0112-0113, (2020/11/30)
A pyrazole derivative having the following formula stru-1: The pyrazole derivative is used for prevention and control of pests.
Erufosine (ErPC3) Cationic Prodrugs as Dual Gene Delivery Reagents for Combined Antitumor Therapy
Gaillard, Boris,Seguin, Cendrine,Remy, Jean-Serge,Pons, Fran?oise,Lebeau, Luc
, p. 15662 - 15679 (2019/11/14)
Sixteen cationic prodrugs of the antitumor alkylphospholipid (APL) erufosine were rationally synthesized to provide original gene delivery reagents with improved cytotoxicity profile. The DNA complexation properties of these cationic lipids were determined and associated transfection rates were measured. Furthermore, the self-assembly properties of the pro-erufosine compounds were investigated and their critical aggregation concentration was determined. Their hydrolytic stability under pH conditions mimicking the extracellular environment and the late endosome milieu was measured. Hemolytic activity and cytotoxicity of the compounds were investigated. The results obtained in various cell lines demonstrate that the prodrugs of erufosine display antineoplastic activity similar to that of the parent antitumor drug but are not associated with hemolytic toxicity, which is a dose-limiting side effect of APLs and a major obstacle to their use in anticancer therapeutic regimen. Furthermore, by using lipoplexes prepared from a prodrug of erufosine and a plasmid DNA encoding a pro-apoptotic protein (TRAIL), evidence was provided for selective cytotoxicity towards tumor cells while nontumor cells were resistant. This study demonstrates that the combination approach involving well tolerated erufosine cationic prodrugs and cancer gene therapy holds significant promise in tumor therapy.
COMPOUNDS WITH HIV MATURATION INHIBITORY ACTIVITY
-
Page/Page column 12, (2019/11/12)
The present invention relates to compound of Formula I or a pharmaceutically acceptable salt thereof (Formula I) wherein R1 is Formula (AA) or Formula (BB) where the squiggly line indicates the point of attachment to the rest of the molecule; R2 is F or Formula (CC) where the squiggly line indicates the point of attachment to the rest of the molecule; R3 is H or CH3; Z is O or is absent; and R4 is -OC1-3alkyl, C1-30alkyl, or -N(CH3)2.
A class of pyrazole derivatives, preparation method and application thereof (by machine translation)
-
Paragraph 0203; 0219; 0222; 0223; 0224, (2018/10/11)
The invention discloses a following formula stru - 1 indicated by the pyrazole derivatives, The definition of each substituent in the specification. This invention relates to pyrazole derivatives suitable for use in the pest. (by machine translation)
Substituted aza indole compounds and salts thereof, composition and use thereof
-
Paragraph 0375; 0377; 0378, (2018/11/03)
The invention provides a substituted azaindole compound having a structure as represented by a formula (I) and a pharmaceutically acceptable salt and a medicinal preparation thereof. The compound is used for adjusting activity of protein kinase and adjusting intercellular or intracellular signal response. The invention further relates to a pharmaceutical composition including the compound and a method of applying the pharmaceutical composition to treatment of highly proliferative diseases of mammals, especially of mankind.
Prodrugs of NH-acidic compounds
-
Page/Page column 426, (2015/11/16)
The invention provides a method of sustained delivery of a lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug by administering to a patient an effective amount of a prodrug compound of the invention wherein upon administration to the patient, release of the parent drug from the prodrug is sustained release. Prodrug compounds suitable for use in the methods of the invention are labile conjugates of parent drugs that are derivatized through carbonyl linked prodrug moieties. The prodrug compounds of the invention can be used to treat any condition for which the lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug is useful as a treatment.
SUBSTITUTED AZAINDOLE COMPOUNDS, SALTS, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS OF USE
-
Paragraph 0289-0290, (2014/03/24)
The present invention provides substituted azaindole prodrugs, methods of making said prodrugs, pharmaceutical compositions of said prodrugs and methods of using said prodrugs and pharmaceutical compositions thereof to treat or prevent diseases or disorders such as cancer.
Synthesis of acyloxyalkyl esters of thiocarbonic and dithiocarbamic acids
Mustafaev,Kulieva,Mustafaev,Kulibekova,Kakhramanova,Safarova,Novotorzhina
, p. 198 - 203 (2013/07/25)
Reactions of acyloxyalkyl chloride with alkaline salts of alkylxanthic, butyltrithiocarbonic, and diethyldithiocarbamic acids afforded a series of acyloxyalkyl esters of various nature and positions of the acyl groups in the molecule.
SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS
-
Page/Page column 93-94, (2012/10/18)
The present invention relates to the synthesis and application of novel chiral/ achiral substituted methyl formyl reagents to modify pharmaceutical agents and/or biologically active substances to modify the physicochemical, biological and/or pharmacokinetic properties of the resulting compounds from the unmodified original agent.
